At least I got a few serious posts on the top of the thread on MPAC and other drug demyelination toxicities before you clowns wrecked the thread. I think it is useful to investors to understand what the toxicity in question is so they can decide what the chances of approval in the EU are. Unfortunately the company as usual left us guessing.
Demyelination issues are probably the cause of the problem at overdose levels. I was hoping to get some comment from someone who understands the issue. All I got was a monkey who thinks the only patient with vision problems ever seen in an MPAC Prana trial had the symptoms rapidly reverse when the 375mg treatment was stopped, is irrelevant.
What was it the FDA asked?
Approved drugs with CNS demyelination side effect., page-11
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $8.75K | 1.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 59 | 63306661 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 28430837 | 21 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |